Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

• Higher levels of short-chain fatty acids like acetate and butyrate may positively influence CAR-T therapy outcomes.
• Data show variations in systemic short-chain fatty acid profiles before and after CAR-T infusion in myeloma patients.
• The study focuses on the role of microbiota in metabolic and immune responses related to cancer immunotherapy.
• Post-CAR T-cell infusion changes in fatty acid profiles could correlate with treatment efficacy in myeloma.